In the ongoing story of medical innovation meeting capital markets, Establishment Labs — the company behind Motiva Implants — will bring its chief executive and financial officer before healthcare investors at the Jefferies Virtual Healthcare Conference on June 4, 2021. The Costa Rica-based device maker, whose silicone gel implants are available in over eighty countries, uses such moments to translate clinical progress and regulatory milestones into the language of institutional confidence. It is a familiar ritual of modern medicine: science seeking the sustained attention of those who fund it
Establishment Labs to Present at Jefferies Virtual Healthcare Conference
Building the evidence base that surgeons and patients will trust
Mark
Why does a medical device company need to present at a healthcare investor conference? Isn't that just routine corporate communication?
Mimi
It is routine, but the timing and the people matter. This is a company that got FDA approval to run clinical trials in the U.S. just three years earlier. They're still building the evidence base that American surgeons and patients will need to trust the product. A conference like Jefferies is where institutional investors decide whether to believe in the company's growth story.
Mark
So the clinical trial data is the real story here?
Mimi
It's part of it. But also the global reach—eighty countries already using the product, manufacturing at scale, regulatory compliance across multiple jurisdictions. They're not a startup anymore. They're proving they can operate like a real medical device company.
Mark
What's the Divina system they mention?
Mimi
A 3D simulation tool. It lets surgeons and patients visualize outcomes before surgery. It's the kind of thing that sounds small but changes the patient experience and reduces revision surgeries. It's part of the ecosystem they're building around the implants themselves.
Mark
Does the fact that they're presenting on the last day of the conference matter?
Mimi
It could. Friday afternoon is when attention starts to drift, but it's also when serious investors who've been taking notes all week come back to companies they're genuinely interested in. Establishment Labs clearly thinks their story is worth that slot.
O Pulso
- A company with global reach but an unfinished American story steps into the spotlight, still navigating FDA clinical trials launched in 2018.
- CEO Juan José Chacón-Quirós and CFO Renee Gaeta will face healthcare investors on June 4, carrying the weight of both clinical data and market expectations.
- The Jefferies Virtual Healthcare Conference compresses four days of industry scrutiny into a single high-stakes presentation window at 2:00 pm Eastern.
- Beyond the live audience, a streamed and recorded presentation signals the company's intent to reach every corner of the investment community, not just those in the room.
In the ongoing story of medical innovation meeting capital markets, Establishment Labs — the company behind Motiva Implants — will bring its chief executive and financial officer before healthcare investors at the Jefferies Virtual Healthcare Conference on June 4, 2021. The Costa Rica-based device maker, whose silicone gel implants are available in over eighty countries, uses such moments to translate clinical progress and regulatory milestones into the language of institutional confidence. It is a familiar ritual of modern medicine: science seeking the sustained attention of those who fund its future.
Establishment Labs, the Nasdaq-listed medical device company behind Motiva Implants, will present at the Jefferies Virtual Healthcare Conference on June 4, 2021. CEO and founder Juan José Chacón-Quirós and CFO Renee Gaeta are scheduled to address healthcare investors at 2:00 pm Eastern, on the final day of the four-day event.
The company designs and manufactures silicone gel-filled breast implants for cosmetic and reconstructive use, produced at facilities certified to international standards including ISO 13485:2016 and FDA compliance under the MDSAP program. Motiva Implants form the heart of the broader MotivaImagine platform, which also includes the Divina 3D Simulation System and other tools supporting surgeons and patients through the aesthetic and reconstructive process.
With distribution across more than eighty countries through both exclusive partners and a direct sales force, Establishment Labs has built considerable global presence. Its American ambitions advanced meaningfully in 2018, when the FDA granted an investigational device exemption allowing a U.S. clinical trial to begin that April.
The Jefferies presentation will offer institutional investors a direct look at the company's clinical progress, regulatory trajectory, and strategic direction. For those unable to attend, the session will be streamed live on the company's investor relations website and made available as a recording afterward.
Establishment Labs, the medical device company behind Motiva Implants, will send its top two executives to speak with healthcare investors at the Jefferies Virtual Healthcare Conference in early June. CEO and founder Juan José Chacón-Quirós and Chief Financial Officer Renee Gaeta are scheduled to present on Friday, June 4, 2021, at 2:00 pm Eastern time, during the four-day conference running June 1-4.
The company, which trades on the Nasdaq under the ticker ESTA, designs and manufactures silicone gel-filled breast implants for both cosmetic and reconstructive purposes. Motiva Implants represent the core of what the company calls the MotivaImagine platform—a suite of products and services aimed at the breast aesthetics and reconstruction market. The implants are produced at two manufacturing facilities that meet strict international standards, including ISO 13485:2016 certification and FDA compliance under the MDSAP program.
Establishment Labs has built a global footprint, with Motiva Implants now available in more than eighty countries through a combination of exclusive distributors and the company's own direct sales team. The company's clinical ambitions in the United States took a significant step forward in 2018, when the FDA granted an investigational device exemption that allowed Establishment Labs to launch a clinical trial for Motiva Implants in the American market, beginning in April of that year.
Beyond the implants themselves, the company's portfolio includes the Divina 3D Simulation System and other complementary products and services designed to support surgeons and patients throughout the aesthetic and reconstructive process. The Jefferies presentation will give institutional investors and conference attendees a chance to hear directly from leadership about the company's progress, clinical data, and strategic direction.
For those unable to attend the conference in person, Establishment Labs will stream the presentation live on its investor relations website. A recorded version will remain available afterward for anyone who wants to review the remarks or catch what they missed. The company has positioned this appearance as an opportunity to update the investment community on developments across its business, from manufacturing and regulatory milestones to the expanding clinical evidence supporting its products.
Citações Notáveis
Establishment Labs manufactures Motiva Implants at two facilities meeting ISO 13485:2016 and FDA 21 CFR 820 standards under the MDSAP program— Company statement
Quer a matéria completa?
Leia o original em Markets Insider ↗
Economy & Finance